Product Description
Mechanisms of Action: S1P1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sloan Kettering Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hypertriglyceridemia|Liver Cancer|Thrombophlebitis|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SPOC-2010-002 | P1 |
Terminated |
Thrombophlebitis|Liver Cancer|Hypertriglyceridemia |
2020-12-01 |
|
| MSKCC-04002 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2009-02-01 |